Under a tenth of patients eligible to benefit from obesity jabs like Wegovy are able to get them, warns the World Health Organization as it releases its first advice on the medications.
With in excess of 1,000,000,000 individuals worldwide currently obese, it is advocating for broader and more equitable availability to these injectable treatments.
According to estimates, in excess of 2,000,000,000 could be obese by 2030 if no action is taken.
"The new guidelines recognises that obesity is a lifelong illness that can be managed with holistic and ongoing care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are significant barriers to broad availability to the jabs that can assist patients in reducing significant body mass, notes the agency.
Skinny Jab Shortage
Despite the current best projected scenario, the manufacturing of these medications could only cover approximately 100 million people – less than 10% of those who need them, as stated by the WHO.
The recommendation encourages nations and manufacturers to expand availability, through measures including patent sharing.
A patent on a key compound – the primary component of Novo Nordisk's Wegovy – is due to expire in several countries in 2026.
How Weight-Loss Drugs Function
The injections replicate a natural hormone to reduce digestion speed, reduce hunger and boost the sense of being full so people reduce food intake.
Individuals typically see weight reduction after several weeks of starting on the once-weekly jabs.
Evidence indicates users may regain a significant portion a year later of discontinuing the drug, because their usual food cravings resume.
Being overweight or obese raises your likelihood for contracting diseases, such as diabetes, cardiovascular issues, brain attack, and some cancers.
Excess weight concerns individuals in every country and was associated with millions of fatalities worldwide in 2024, as per the WHO.
